Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients

October 11, 2018 updated by: Sherman Xuegang Xin, Southern Medical University, China

Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients In Vivo

Studies have shown that tumor specific amplitude-modulated frequencies of radiofrequency electromagnetic fields that is associated with biofeedback upon exposure to in cancer patients. However, such discovery in other cancer patients are rare. And whether tumor specific frequencies can be found in Asian cancer patients remains unclear. The purpose of this study is to detect the tumor specific frequencies of Asian cancer patients in vivo.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The measurements were safety guaranteed and were conducted in hospital. Before detecting, the patient will be already diagnosed with cancer. The doctor and the operator are responsible for the detecting. When cancer patients are exposure to the RF electromagnetic fields, the radial pulse amplitude, blood pressure, skin electrical resistance and breath will be monitored. Biofeedback parameters will be recorded at different modulation frequencies and analyzed in order to find the variation and tumor specific frequencies.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Xin Sherman Xuegang, professor
  • Phone Number: 008613602733465
  • Email: xxg@smu.edu.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  1. The patients who are diagnosed with cancer disease
  2. Healthy participators

Description

Inclusion Criteria:

  • Clinical diagnosis of cancer Disease

Exclusion Criteria:

  • other patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
cancer patients
Low intensity amplitude-modulated RF EMFs
Device: Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
Other Names:
  • Low intensity AM RF EMFs
healthy participators
Low intensity amplitude-modulated RF EMFs
Device: Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
Other Names:
  • Low intensity AM RF EMFs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Biofeedback response of cancer patients at the exposure of Low intensity amplitude-modulated radiofrequency electromagnetic fields
Time Frame: within 20 min of exposure
within 20 min of exposure

Secondary Outcome Measures

Outcome Measure
Time Frame
Representation of autonomous response during the exposure of tumor specific frequencies modutated RF eletromagnetic fields
Time Frame: within 20 min of exposure
within 20 min of exposure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Southern Medical University, China

Collaborators

Nanfang Hospital of Southern Medical University
Guangdong 999 Brain Hospital
The 157th Hospital of PLA,China

Investigators

  • Principal Investigator: Xin Sherman Xuegang, professor, School of Biomedical Engineering,Southern Medical University
  • Study Director: Cai Linbo, master, Guangdong 999 Brain Hospital
  • Study Director: Zhu Xiaoxia, PhD, Nanfang Hospital of Southern Medical University
  • Study Director: Liu Xiantang, bachelor, The 157th Hospital of PLA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 1, 2018

Primary Completion (Anticipated)

June 1, 2019

Study Completion (Anticipated)

June 1, 2020

Study Registration Dates

First Submitted

July 6, 2016

First Submitted That Met QC Criteria

July 6, 2016

First Posted (Estimate)

January 31, 2017

Study Record Updates

Last Update Posted (Actual)

October 12, 2018

Last Update Submitted That Met QC Criteria

October 11, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • SXXin-AM-RF-EMF-in vivo

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Clinical Trials on Low intensity amplitude-modulated RF EMFs

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe